Head-to-head · WeighScore
Corsica Health vs Gala Health
The verdict
Gala Health takes it — 82.9/100 to 66.3/100.
Gala Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A compounded tirzepatide and semaglutide program for women that reaches all 50 states and keeps a brand-name Ozempic path open — but its $179 and $149 headline rates are yearly-subscription prices, not monthly ones.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Corsica Health | Gala Health |
|---|---|---|
| WeighScore | 66.3/100 | 82.9/100 |
| Grade | C | B− |
| Scorecard rank | #188 | #17 |
| Semaglutide | $249/mo (compounded) | Not disclosed |
| Tirzepatide | $349/mo (compounded) | $179/mo (yearly subscription) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #188 · C
Strengths
- Public pricing shown for both compounded and brand-name options — a real transparency advantage
- $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
- LegitScript Certified
- Clear 3-step intake: Assessment, Provider Review, Receive Medication
- $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced
Where it loses points
- Legal entity name and state of incorporation not disclosed on the site
- Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
- Per-state availability not listed publicly
- First-month promotional pricing not disclosed
- Lab-work inclusion not clearly disclosed
Graded #17 · B−
Strengths
- Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
- Prices are published openly rather than quiz-gated, with all doses included at the one rate
- All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet — injection only
- Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.